Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07344064

The Effects of Adjunctive Therapy With Vaginal Tablets Lactobacillus Acidophilus and a Low Dose Estriol (Gynoflor®) to Prolong Pregnancy Time in Preterm Labor, A Randomized Controlled Trial

The study aim to study The Adjunctive therapy with vaginal tablets containing Lactobacillus acidophilus KS400 and low-dose Estriol (Gynoflor®) in addition to standard tocolytic treatment administered once daily for 6 days starting the same day as tocolytic therapy, in pregnant women diagnosed with preterm labor at gestational age 24-33 weeks .Primary Outcome is the rate of pregnancy prolongation beyond 7 days after initiation of tocolytic therapy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Participants in the intervention group are pregnant women diagnosed with preterm labor between 24 and 33 weeks of gestation. They receive:

  • Gynoflor® vaginal tablets (containing Lactobacillus acidophilus KS400 and 0.03 mg estriol)
  • Dosage: 1 tablet inserted vaginally at bedtime for 6 consecutive days
  • Start time: On the same day as starting standard tocolytic therapy (such as nifedipine, terbutaline, or magnesium sulfate)
  • Purpose: To restore healthy vaginal flora, reduce risk of ascending infection, and potentially prolong pregnancy duration

The control group receives only standard tocolytic therapy, without Gynoflor®.

Outcomes (Detailed Description):

Primary Outcome:

  • Rate of pregnancy prolongation beyond 7 days from the initiation of tocolytic therapy

Secondary Outcomes:

  • Gestational age at delivery ≥34 weeks
  • Length of hospital stay (in days)
  • Use of second-line tocolytic agents (e.g., switching due to inefficacy or side effects)
  • Readmission within 14 days after discharge
  • Incidence of side effects from Gynoflor® (especially local symptoms like vaginal burning or irritation)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women diagnosed with preterm labor or threatened preterm labor, with a gestational age between 24 and 33 weeks, who are receiving tocolytic therapy.

Exclusion criteria

  • Age under 18 years or 35 years and older
  • Incomplete course of Gynoflor® (less than 6 days of use)
  • Presence of contraindications to tocolysis
  • Preterm premature rupture of membranes (PPROM)
  • Unable to be contacted for follow-up
  • History of allergy to probiotics or Gynoflor®
  • Multiple gestation
  • History of short cervix diagnosed between 16-24 weeks of gestation
  • History of previous preterm labor (PTL)
  • Pregnancy achieved via assisted reproductive technology (ART)
  • Presence of fetal anomaly
  • History of antepartum hemorrhage
  • Substance abuse, including cigarette smoking, alcohol, cocaine, or heroin use
  • Other causes of preterm labor such as uterine overdistension (e.g., polyhydramnios, multifetal gestation), uterine abnormalities (e.g., myoma uteri), or systemic infections, except vaginitis

Treatment and study plan

Gynoflor

Drug

Participants in this group will receive Gynoflor vaginal tablets (containing Lactobacillus acidophilus and estriol) administered once daily for 7 consecutive days. This intervention aims to evaluate whether restoring vaginal flora with Gynoflor can prolong pregnancy time compared to no intervention.

Primary outcomes

  1. proportion of women remaining pregnant more than 7 days after initiation of tocolytic

    Time frame: within 7 days from the start of tocolytic

Sponsors and collaborators

Lead sponsor

Queen Savang Vadhana Memorial Hospital, Thailand

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 15, 2026
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.